Why the Rare Disease Bio that Withdrawn DMD New Drug Rebounded to 2%

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) closed at $85.44, up 2.56% from the previous session. Trading volume was approximately 3.28 million shares, and market capitalization increased by about $186 million (roughly KRW 250 billion) in one day to around $7.1 billion (approximately KRW 9.7 trillion).

In its first-quarter results announced in May, the company highlighted revenue growth driven by its rare disease therapy Sefiens, outlined value-creation events slated for 2026, and revealed plans to initiate a registrational study of vatiquinone in the third quarter—factors that have bolstered pipeline expectations. (sec.gov) Conversely, in February, PTC Therapeutics voluntarily withdrew its resubmission of a New Drug Application in the U.S. for Translarna, a treatment for Duchenne muscular dystrophy, exposing a significant pipeline risk. (marketscreener.com)

Headquartered in New Jersey, PTC Therapeutics is a biotech company specializing in rare and genetic diseases, focusing on small molecules and gene therapies that target gene expression and splicing. Its rare-disease-centric pipeline includes the oral phenylketonuria therapy Sefiens, the AADC deficiency gene therapy Upstaza, and the Huntington’s disease candidate Botoflam, earning it recognition as a rare-disease specialist. (en.wikipedia.org)